Ocular Therapeutix Research Coverage Started at RBC Capital (OCUL)
Research analysts at RBC Capital initiated coverage on shares of Ocular Therapeutix (NASDAQ:OCUL) in a report released on Tuesday, TheFlyOnTheWall.com reports. The firm set an “outperform” rating and a $21.00 price target on the stock. RBC Capital’s price target suggests a potential upside of 62.16% from the company’s current price.
Ocular Therapeutix (NASDAQ:OCUL) opened at 14.33 on Tuesday. Ocular Therapeutix has a 1-year low of $11.90 and a 1-year high of $15.249. The stock has a 50-day moving average of $13.32 and a 200-day moving average of $13.32. The company’s market cap is $294.8 million.
Ocular Therapeutix, Inc is a biopharmaceutical company focused on the development and commercialization of therapies for diseases and conditions of the eye using its hydrogel platform technology.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.